Association analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet's disease risk in Western Algeria

Frontiers in Immunology

Volumn 4, Issue OCT, 2013, Pages

  Khaib Dit Naib, Ouahiba ^a   Aribi, Mourad ^a   Idder, Aicha ^b   Chiali, Amel ^c   Sairi, Hakim ^c   Touitou, Isabelle ^d,e,f   Lefranc, Gérard ^g   Barat Houari, Mouna ^d  

^a UNIVERSITY OF TLEMCEN   (Algeria)

^b EHU   (Algeria)

^c CHU Oran   (Algeria)

^d MONTPELLIER UNIVERSITY HOSPITAL   (France)

^e UNIV MONTPELLIER   (France)

^f INSERM   (France)

^g CNRS and University Montpellier II   (France)

Author keywords

Beh et's disease; Genetic association; IL10; IL23R IL12RB2; Single nucleotide polymorphism; TNF ; Western Algeria

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 23 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALGERIA; ALLELE; ARTHRITIS; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; ELECTROPHORESIS; EYE INJURY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENITAL ULCER; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOUTH ULCER; POLYMERASE CHAIN REACTION; RISK; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DEFECT; SPECTROPHOTOMETRY;

EID: 84930672893     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00342     Document Type: Article

References (76)

1. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLoS Med (2006) 3:e297. doi:10.1371/journal.pmed.0030297
2. Krause I, Weinberger A. Behçet's disease. Curr Opin Rheumatol (2008) 20:82-7. doi:10.1097/BOR.0b013e3282f154d1
3. Suzuki Kurokawa M, Suzuki N. Behcet's disease. Clin Exp Med (2004) 4:10-20. doi:10.1007/s10238-004-0033-4
4. Yazici H, Esen F. Mortality in Behçet's syndrome. Clin Exp Rheumatol (2008) 26(Suppl 51):S138-40.
5. Fietta P. Behçet's disease: familial clustering and immunogenetics. Clin Exp Rheumatol (2005) 23(Suppl 38):S96-105.
6. De Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behçet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum (2009) 61:1287-96. doi:10.1002/art.24642
7. Ohno S, Aoki K, Sugiura S, Nakayama E, Itakura K, Aizawa M. HLA-B5 and Behçet's disease. Lancet (1973) 302:1383-4. doi:10.1016/S0140-6736(73)93343-6
8. Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behçet's disease. Arch Ophthalmol (1982) 100:1455-8. doi:10.1001/archopht.1982.01030040433013
9. Mizuki N, Inoko H, Mizuki N, Tanaka H, Kera J, Tsuiji K, et al. Human leukocyte antigen serologic and DNA typing of Behçet's disease and its primary association with B51. Invest Ophthalmol Vis Sci (1992) 33:3332-40.
10. Yazici H, Fresko I, Yurdakul S. Behcet's syndrome: disease manifestations, management, and advances in treatment. Nat Clin Pract Rheumatol (2007) 3:148-55. doi:10.1038/ncprheum0436
11. Karasneh J, Gül A, Ollier WE, Silman AJ, Worthington J. Whole-genome screening for susceptibility genes in multicase families with Behçet's disease. Arthritis Rheum (2005) 52:1836-42. doi:10.1002/art.21060
12. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behçet's disease using a genome-wide association study. Arthritis Res Ther (2009) 11:R66. doi:10.1186/ar2695
13. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's disease. Nat Genet (2010) 42:698-702. doi:10.1038/ng.625
14. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behçet's disease susceptibility loci. Nat Genet (2010) 42:703-6. doi:10.1038/ng.624
15. Esin S, Gül A, Hodara V, Jeddi-Tehrani M, Dilsen N, Koniçe M, et al. Peripheral blood T cell expansions in patients with Behcet's disease. Clin Exp Immunol (1997) 107:520-7.
16. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol (1999) 118:451-7.
17. Direskeneli H. Behcet's disease: infectious aetiolozgy, new autoantigens, and HLA-B51. Ann Rheum Dis (2001) 60:996-1002. doi:10.1136/ard.60.11.996
18. Kulaber A, Tugal-Tutkun I, Yentür SP, Akman-Demir G, Kaneko F, Gül A, et al. Pro-inflammatory cellular immune response in Behçet's disease. Rheumatol Int (2007) 27:1113-8. doi:10.1007/s00296-007-0367-9
19. Raziuddin S, al-Dalaan A, Bahabri S, Siraj AK, al-Sedairy S. Divergent cytokine production profile in Behçet's disease. Altered Th1/Th2 cell cytokine pattern. J Rheumatol (1998) 25:329-33.
20. Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K. Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol (2002) 31:205-10. doi:10.1080/030097402320318387
21. Ben Ahmed M, Houman H, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum (2004) 50:2291-5. doi:10.1002/art.20334
22. Lee EB, Kim JY, Lee YJ, Park MH, Song YW. TNF and TNF receptor polymorphisms in Korean Behcet's disease patients. Hum Immunol (2003) 64:614-20. doi:10.1016/S0198-8859(03)00057-0
23. Akdeniz N, Esrefoglu M, Keles MS, Karakuzu A, Atasoy M. Serum interleukin-2, interleukin-6, tumour necrosis factor-alpha and nitric oxide levels in patients with Behcet's disease. Ann Acad Med Singapore (2004) 33:596-9.
24. Oztas MO, Onder M, Gurer MA, Bukan N, Sancak B. Serum interleukin 18 and tumour necrosis factor-alpha levels are increased in Behcet's disease. Clin Exp Dermatol (2005) 30:61-3. doi:10.1111/j.1365-2230.2004.01684.x
25. Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol (1992) 10:411-52. doi:10.1146/annurev.iy.10.040192.002211
26. Hofmann SR, Rösen-Wolff A, Tsokos GC, Hedrich CM. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol (2012) 143:116-27. doi:10.1016/j.clim.2012.02.005
27. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol (2012) 32:23-63. doi:10.1615/CritRevImmunol.v32.i1.30
28. Dai H, Ciric B, Zhang GX, Rostami A. Interleukin-10 plays a crucial role in suppression of experimental autoimmune encephalomyelitis by Bowman-Birk inhibitor. J Neuroimmunol (2012) 245:1-7. doi:10.1016/j.jneuroim.2012.01.005
29. Makhatadze NJ. Tumor necrosis factor locus: genetic organisation and biological implications. Hum Immunol (1998) 59:571-9. doi:10.1016/S0198-8859(98)00056-1
30. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol (2001) 19:683-765. doi:10.1146/annurev.immunol.19.1.683
31. Lio D, Candore G, Colombo A, Colonna Romano G, Gervasi F, Marino V, et al. A genetically determined high setting of TNF alpha influences immunological parameters of HLA-B8, DR3 positive subjects: implications for autoimmunity. Hum Immunol (2001) 62:705-13. doi:10.1016/S0198-8859(01)00264-6
32. Candore G, Lio D, Colonna Romano G, Caruso C. Pathogenesis of autoimmune diseases associated with 8.1 ancestral haplotype: effect of multiple gene interactions. Autoimmun Rev (2002) 1:29-35. doi:10.1016/S1568-9972(01)00004-0
33. Belguendouz H, Messaoudène D, Lahmar K, Ahmedi L, Medjeber O, Hartani D, et al. Interferon-? and nitric oxide production during Behçet uveitis: immunomodulatory effect of interleukin-10. J Interferon Cytokine Res (2011) 31:643-51. doi:10.1089/jir.2010.0148
34. Arayssi T, Hamra R, Homeidan F, Uthman I, Awwad ST, Mroue K, et al. The efficacy of a single dose of infliximab in the treatment of Behcet's disease uveitis. Clin Exp Rheumatol (2005) 23:427.
35. Sfikakis PP, Markomichelakis N, Alpsoy E, Assaad-Khalil S, Bodaghi B, Gul A, et al. Anti-TNF therapy in the management of Behcet's disease review and basis for recommendations. Rheumatology (Oxford) (2007) 46:736-41. doi:10.1093/rheumatology/kem034
36. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet (1997) 24:1-8. doi:10.1111/j.1365-2370.1997.tb00001.x
37. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation. Proc Natl Acad Sci U S A (1997) 94:3195-9. doi:10.1073/pnas.94.7.3195
38. Wallace GR, Kondeatis E, Vaughan RW, Verity DH, Chen Y, Fortune F, et al. IL-10 genotype analysis in patients with Behçet's disease. Hum Immunol (2007) 68:122-7. doi:10.1016/j.humimm.2006.11.010
39. Ates O, Dalyan L, Hatemi G, Hamuryudan V, Topal-Sarikaya A. Analyses of functional IL10 and TNF-α genotypes in Behçet's syndrome. Mol Biol Rep (2010) 37:3637-41. doi:10.1007/s11033-010-0015-4
40. Ahmad T, Wallace GR, James T, Neville M, Bunce M, Mulcahy-Hawes K, et al. Mapping the HLA association in Behçet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum (2003) 48:807-13. doi:10.1002/art.10815
41. Kamoun M, Chelbi H, Houman MH, Lacheb J, Hamzaoui K. Tumor necrosis factor gene polymorphisms in Tunisian patients with Behcet's disease. Hum Immunol (2007) 683:201-5. doi:10.1016/j.humimm.2006.12.006
42. Touma Z, Farra C, Hamdan A, Shamseddeen W, Uthman I, Hourani H, et al. TNF Polymorphisms in patients with Behçet's disease: a meta-analysis. Arch Med Res (2010) 41:142-6. doi:10.1016/j.arcmed.2010.02.002
43. Radouane A, Oudghiri M, Chakib A, Bennani S, Touitou I, Barat-Houari M. SNPs in the TNF-a gene promoter associated with Behçet's disease in Moroccan patients. Rheumatology (Oxford) (2012) 51:1595-9. doi:10.1093/rheumatology/kes141
44. Guenane H, Hartani D, Chachoua L, Lahlou-Boukoffa OS, Mazari F, Touil-Boukoffa C. Production of Th1/Th2 cytokines and nitric oxide in Behçet's uveitis and idiopathic uveitis. J Fr Ophtalmol (2006) 29:146-52. doi:JFO-02-2006-29-2-0181-5512-101019-200508206
45. Belguendouz H, Messaoudene D, Hartani D, Chachoua L, Ahmedi ML, Lahmar-Belguendouz K, et al. Effect of corticotherapy on interleukin-8 and -12 and nitric oxide production during Behçet and idiopathic uveitis. J Fr Ophtalmol (2008) 31:387-95. doi:10.1016/S0181-5512(08)71433-5
46. Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X, et al. Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. Mol Vis (2010) 19:880-6.
47. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med (2005) 201:233-40. doi:10.1084/jem.20041257
48. Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev (2008) 226:248-62. doi:10.1111/j.1600-065X.2008.00704.x
49. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet (1990) 335:1078-80.
50. Glasel JA. Validity of nucleic acid purities monitored by 260nm/280nm absorbance ratios. Biotechniques (1995) 18:62-3.
51. Ding Q, Fan B, Fan Z, Ding L, Li F, Tu W, et al. Interleukin-10-819C >T polymorphism contributed to cancer risk: evidence from 29 studies. Cytokine (2012) 61:139-45. doi:10.1016/j.cyto.2012.09.008
52. Xue H, Wang YC, Lin B, An J, Chen L, Chen J, et al. A meta-analysis of interleukin-10-592 promoter polymorphism associated with gastric cancer risk. PLoS One (2012) 7:e39868. doi:10.1371/journal.pone.0039868
53. Li D, He Q, Li R, Xu X, Chen B, Xie A. Interleukin-10 promoter polymorphisms in Chinese patients with Parkinson's disease. Neurosci Lett (2012) 513:183-6. doi:10.1016/j.neulet.2012.02.033
54. Zhong Q, Ding C, Wang M, Sun Y, Xu Y. Interleukin-10 gene polymorphisms and chronic/aggressive periodontitis susceptibility: a meta-analysis based on 14 case-control studies. Cytokine (2012) 60:47-54. doi:10.1016/j.cyto.2012.05.014
55. Liang X, Zhang J, Zhu Y, Lu Y, Zhou X, Wang Z, et al. Specific genetic polymorphisms of IL10-592AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients. Clin Transl Oncol (2013) 15:331-4. doi:10.1007/s12094-012-0936-6
56. Temple SE, Lim E, Cheong KY, Almeida CA, Price P, Ardlie KG, et al. Alleles carried at positions -819 and -592 of the IL10 promoter affect transcription following stimulation of peripheral blood cells with Streptococcus pneumoniae. Immunogenetics (2003) 55:629-32. doi:10.1007/s00251-003-0621-6
57. Lin WP, Lin JH, Chen XW, Wu CY, Zhang LQ, Huang ZD, et al. Interleukin-10 promoter polymorphisms associated with susceptibility to lumbar disc degeneration in a Chinese cohort. Genet Mol Res (2011) 10:1719-27. doi:10.4238/vol10-3gmr1283
58. Tesse R, Del Vecchio GC, De Mattia D, Sangerardi M, Valente F, Giordano P. Association of interleukin-(IL)10 haplotypes and serum IL-10 levels in the progression of childhood immune thrombocytopenic purpura. Gene (2012) 505:53-6. doi:10.1016/j.gene.2012.05.050
59. Xavier JM, Shahram F, Davatchi F, Rosa A, Crespo J, Abdollahi BS, et al. Association study of IL10 and IL23R-IL12RB2 in Iranian patients with Behçet's disease. Arthritis Rheum (2012) 64:2761-72. doi:10.1002/art.34437
60. Jang WC, Nam YH, Ahn YC, Lee SH, Park SH, Choe JY, et al. Interleukin-17F gene polymorphisms in Korean patients with Behcet's disease. Rheumato Int (2008) 29:173-8. doi:10.1007/s00296-008-0664-y
61. Jiang Z, Yang P, Hou S, Du L, Xie L, Zhou H, et al. IL-23R gene confers susceptibility to Behcet's disease in a Chinese Han population. Ann Rheum Dis (2010) 69:1325-8. doi:10.1136/ard.2009.119420
62. Kim ES, Kim SW, Moon CM, Park JJ, Kim TI, Kim WH, et al. Interactions between IL17A, IL23R, and STAT4 polymorphisms confer susceptibility to intestinal Behcet's disease in Korean population. Life Sci (2012) 90:740-6. doi:10.1016/j.lfs.2012.03.017
63. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu Rev Immunol (2007) 25:221-42. doi:10.1146/annurev.immunol.22.012703.104758
64. Paunovic V, Carroll HP, Vandenbroeck K, Gadina M. Signalling, inflammation and arthritis: crossed signals: the role of interleukin (IL)-12, -17, -23 and -27 in autoimmunity. Rheumatology (2008) 47:771-6. doi:10.1093/rheumatology/kem352
65. Hirschfield GM, Liu X, Xu C, Lu Y, Xie G, Lu Y, et al. Primary biliary cirrosis associated with HLA, IL12A and IL12RB2 variants. N Engl J Med (2009) 360:2544-55. doi:10.1056/NEJMoa0810440
66. Liu X, Invernizzi P, Lu Y, Kosoy R, Lu Y, Bianchi I, et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrosis. Nat Genet (2010) 42:658-60. doi:10.1038/ng.627
67. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, et al. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet (2011) 43:329-32. doi:10.1038/ng.789
68. Park K, Kim N, Nam J, Bang D, Lee ES. Association of TNFA promoter region haplotype in Behçet's disease. J Korean Med Sci (2006) 21:596-601. doi:10.3346/jkms.2006.21.4.596
69. Akman A, Sallakci N, Kacaroglu H, Tosun O, Yavuzer U, Alpsoy E, et al. Relationship between periodontal findings and the TNF-alpha gene 1031T/C polymorphism in Turkish patients with Behcet's disease. J Eur Acad Dermatol Venereol (2008) 22:950-7. doi:10.1111/j.1468-3083.2008.02678.x
70. Orchard TR, Chua CN, Ahmad T, Cheng H, Welsh KI, Jewell DP. Uveitis and erythema nodosum in inflammatory bowel isease: clinical features and the role of HLA genes. Gastroenterology (2002) 123:714-8. doi:10.1053/gast.2002.35396
71. Higuchi T, Seki N, Kamizono S, Yamada A, Kimura A, Kato H, et al. Polymorphism of the 5' flanking region of the human tumor necrosis factor (TNF)-alpha gene in Japanese. Tissue Antigens (1998) 51:605-12. doi:10.1111/j.1399-0039.1998.tb03002.x
72. Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm (1995) 46:32-41.
73. Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, et al. Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-alpha gene promoter. Tissue Antigens (1998) 52:359-67. doi:10.1111/j.1399-0039.1998.tb03056.x
74. Skoog T, van't Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J, et al. A common functional polymorphism (C - >A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet (1999) 8:1443-9. doi:10.1093/hmg/8.8.1443
75. Kaijzel EL, Bayley JP, van Krugten MV, Smith L, van de Linde P, Bakker AM, et al. Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun (2001) 2:135-44. doi:10.1038/sj.gene.6363747
76. Jeffreys AJ, Kauppi L, Neumann R. Intensely punctate meiotic recombination in the class II region of the major histocompatibility complex. Nat Genet (2001) 29:217-22. doi:10.1038/ng1001-217